| Literature DB >> 35642124 |
Ojbindra Kc1, Punya Hari Dahal1, Manisha Koirala1, Enas Al Zaghal2.
Abstract
BACKGROUND Severe hypercalcemia is a life-threatening medical emergency. Its possible etiologies are hyperparathyroidism, malignancy, chronic granulomatous diseases, vitamin D intoxication, medication (lithium, thiazine, excessive vitamin A), hyperthyroidism, acromegaly, adrenal insufficiency, pheochromocytoma, milk-alkali syndrome, and immobilization. Dehydration is considered a consequence of hypercalcemia but not the etiology. CASE REPORT We present a case of a 50-year-old woman who presented with headache, nausea, dizziness, and profound weakness, with a serum calcium level of 17.3 mg/dL due to severe dehydration. The other causes of hypercalcemia were diligently excluded with extensive laboratory testing. The patient's calcium level improved with aggressive intravenous hydration. In the subsequent follow-up visits, the calcium level remained within the reference range. The pathophysiology of severe hypercalcemia caused by dehydration is not clear. However, a feedforward mechanism has been proposed to occur, which worsens both dehydration and hypercalcemia. Dehydration as an initial insult leads to mild or transient hypercalcemia due to decreased fluid volume that affects calcium excretion via the kidneys. Subsequently, hypercalcemia interferes with the kidney's ability to concentrate urine, leading to further dehydration. This sets up a vicious loop that worsens both dehydration and hypercalcemia, leading to profound dehydration and severe hypercalcemia. CONCLUSIONS Dehydration is considered a consequence of hypercalcemia but has not been identified as the etiology of severe hypercalcemia. Hyperparathyroidism and malignancy are the most common causes of severe symptomatic hypercalcemia, and dehydration is the diagnosis of exclusion. However, it is imperative to keep dehydration in the differential diagnosis for a patient presenting with severe symptomatic hypercalcemia, as highlighted by our case.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35642124 PMCID: PMC9169683 DOI: 10.12659/AJCR.936204
Source DB: PubMed Journal: Am J Case Rep ISSN: 1941-5923
The laboratory test results at 2 weeks before presentation, on the day of presentation, and 1 week after discharge.
|
|
|
|
|
|
|---|---|---|---|---|
| White blood cells | 4.0–10.0×103/µL | 5.9×103/µL | 8.6×103/µL | 6.4×103/µL |
| Hemoglobin | 12.0–15.5 gm/dL | 12.0 gm/dL | 12.7 gm/dL | 12.0 gm/dL |
| Platelets | 150–450×103/µL | 166×103/µL | 235×103/µL | 239×103/µL |
| Sodium | 135–146 mEq/L | 133 mEq/L | 135 mEq/L | 134 mEq/L |
| Potassium | 3.5–5.3 mEq/L | 4.7 mEq/L | 3.5 mEq/L | 4.9 mEq/L |
| Chloride | 98–110 mEq/L | 110 mEq/L | 101 mEq/L | 102 mEq/L |
| Bicarbonate | 21–30 mM/L | 18 mM/L | 28 mM/L | 22 mM/L |
| Blood urea nitrogen | 7.0–25 mg/dL | 11 mg/dL | 9 mg/dL | 17 mg/dL |
| Creatinine | 0.55–1.02 mg/dL | 0.85 mg/dL | 0.97 mg/dL | 0.94 mg/dL |
| Glomerular filtration rate | mL/min/1.73 sq m | >60 | >60 | >60 |
| Glucose | 65–99 mg/dL | 379 mg/dL | 365 mg/dL | 470 mg/dL |
| Hemoglobin A1c | <6.0% | Not checked | 10.7% | Not checked |
| Calcium | 8.5–10.4 mg/dL | 8.1 mg/dL | 17.3 mg/dL | 9.6 mg/dL |
| Ionized calcium | 1.19–1.29 mM/L | Not checked | 1.95 mM/L | Not checked |
| Albumin | 3.5–4.9 gm/dL | 4.1 gm/dL | 3.6 gm/dL | 5.1 gm/dL |
| Total protein | 6.0–8.3 gm/dL | 5.9 gm/dL | 5.3 gm/dL | 7.4 gm/dL |
| Aspartate transaminase | 2.0–35 U/L | 24 U/L | 19 U/L | 15 U/L |
| Alanine transaminase | 2.0–40 U/L | 29 U/L | 15 U/L | 17 U/L |
| Alkaline phosphatase | 20–125 U/L | 155 U/L | 97 U/L | 147 U/L |
| Total Bilirubin | 0.2–1.5 mg/dL | 0.4 mg/dL | 0.7 mg/dL | 0.6 mg/dL |
The laboratory workup to determine common causes of hypercalcemia.
|
|
|
|
|---|---|---|
| Parathyroid hormone | 12–88 pg/mL | 5 pg/mL |
| Parathyroid hormone related peptide | <4.2 pmol/L | <0.4 pmol/L |
| Thyroid-stimulating hormone | 0.358–3.740 uIU/mL | 1.266 uIU/mL |
| Cortisol | 4.0–22.0 ug/dL | 11.5 ug/dL |
| 25-hydroxy Vitamin D | 30–80 ng/mL | 23 ng/mL |
| 1,25-dihydroxy Vitamin D | 19.9–79.3 pg/mL | 11.2 pg/mL |
| Kappa free light chain | 3.3–19.4 mg/L | 23.9 mg/L |
| Lambda free light chain | 5.7–26.3 mg/L | 20.3 mg/L |
| Kappa/Lambda ratio | 0.26–1.65 | 1.18 |
| Albumin SPE | 2.76–4.61 g/dL | 3.31 g/dL |
| Alpha 1-globulin SPE | 0.25–0.43 g/dL | 0.28 g/dL |
| Alpha 2 SPE* | 0.56–1.05 g/dL | 0.81 g/dL |
| Beta 2 SPE | 0.71–1.16 g/dL | 0.60 g/dL |
| Gamma SPE | 0.58–1.49 g/dL | 0.49 g/dL |
| Serum paraprotein 1 | <0.01 g/dL | 0 g/dL |
| Serum paraprotein 2 | <0.01 g/dL | 0 g/dL |
| Serum paraprotein 3 | <0.01 g/dL | 0 g/dL |
SPE – serum protein electrophoresis.
The degree of hypercalcemia with clinical manifestations.
|
|
|
|
|---|---|---|
| Mild | 10.5–11.9 mg/dL | Usually asymptomatic, constipation, fatigue, depression |
| Moderate | 12–13.9 mg/dL | Anorexia, nausea, polyuria, polydipsia, dehydration, shortened QT interval, muscle weakness, cognitive dysfunction |
| Severe | >14 mg/dL | Lethargy, confusion, stupor, coma, pancreatitis, renal insufficiency, muscle weakness, arrhythmia, ventricular tachycardia |
Corrected calcium(mg/dL)=measured total calcium(mg/dL)+0.8 (4.0-serum albumin (g/dL).